Abstract
The FGF/FGFR signaling axis deregulation of the fibroblast growth factor receptor
(FGFR) family is closely related to tumorigenesis, tumor progression and drug resistance
to anticancer therapy. And fibroblast growth factor receptor 3 (FGFR3) is one member
of this family. In this study, we aimed to investigate the effect of siRNA-induced
knockdown of FGFR3 on the biological behaviors of intrahepatic cholangiocarcinoma
(ICC). The expression levels of FGFR3 were determined in three intrahepatic cholangiocarcinoma
cell lines RBE, HUCCT1 and HCCC9810 cell lines by Western blot. FGFR3 expression in
RBE cell line was knocked down by siRNA. Our study found that knockdown of FGFR3 inhibited
the migration, invasion and proliferation of ICC cells using Wound healing assay,
Transwell migration and invasion assays and Cell proliferation assay. And significantly
down-regulated the protein expression levels of MMP2, cyclinD1, and N Cadherin, but had no significant effect on MMP9, cyclinD3, vimentin, E-cadherin protein.
In addition, we found that ERK/c-Myc presumably is its signaling pathway by bioinformatics
analysis and Western blot verification. To sum up, knockdown of FGFR3 inhibited the
migration, invasion and proliferation of ICC cells. It demonstrated that FGFR3 probably
becomes a therapeutic target for ICC and increases the proportion of potentially curable
intrahepatic cholangiocarcinoma patients treated with FGFR inhibitors.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Histological classification of liver and intrahepatic bile duct cancers in SEER registries[J].J Registry Manag. 2011; 38: 201-205
- Evaluation and recommendation of the 8th edition of American joint committee on cancer (AJCC) staging system for intrahepatic cholangiocarcinoma (ICC) in 820 patients from the surveillance, epidemiology, and end results (SEER) database[J].J Gastrointest Surg. 2021; 25: 145-154
- Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma[J].J Hepatol. 2019; 71: 104-114
- Asbestos and intrahepatic cholangiocarcinoma[J].Cells. 2020; 9
- Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management[J].Cancer Lett. 2016; 379: 198-205
- Surgical options for intrahepatic cholangiocarcinoma[J].Hepatobiliary Surg Nutr. 2017; 6: 79-90
- Small molecules, big impact: 20 years of targeted therapy in oncology[J].The Lancet. 2020; 395: 1078-1088
- Advances and challenges in targeting FGFR signalling in cancer[J].Nat Rev Cancer. 2017; 17: 318-332
- Targeting FGFR Signaling in Cancer[J].Clin Cancer Res. 2015; 21: 2684-2694
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder[J].Pharmacol Res. 2020; 151104567
- Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors[J].Clin Cancer Res. 2020; 26: 764-774
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study[J].Lancet Oncol. 2020; 21: 671-684
- Pemigatinib: first Approval[J].Drugs. 2020; 80: 923-929
- Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma[J].Cancer Discov. 2017; 7: 1116-1135
- Journey of siRNA: clinical developments and targeted delivery[J].Nucleic Acid Ther. 2018; 28: 209-224
- Recent progress in development of siRNA delivery vehicles for cancer therapy[J].Adv Drug Deliv Rev. 2016; 104: 61-77
- Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma[J].Clin Cancer Res. 2016; 22: 291-300
- FGFR3 signaling and function in triple negative breast cancer[J].Cell Commun Signal. 2020; 18: 13
- Aberrant N-cadherin expression in cancer[J].Biomed Pharmacother. 2019; 118109320
- EMT transition states during tumor progression and metastasis[J].Trends Cell Biol. 2019; 29: 212-226
- Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2[J].Mol Oncol. 2020; 14: 1365-1380
- Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies[J].Cancer Biother Radiopharm. 2014; 29: 166-172
- MMP2 expression is a prognostic marker for primary melanoma patients[J].Cell Oncol (Dordr). 2012; 35: 207-216
- Cyclin D degradation by E3 ligases in cancer progression and treatment[J].Semin Cancer Biol. 2020; 67: 159-170
- CyclinD1 inhibits dicer and crucial miRNA expression by chromatin modification to promote the progression of intrahepatic cholangiocarcinoma[J].J Exp Clin Cancer Res. 2019; 38: 413
- c-MYC-induced genomic instability[J].Cold Spring Harb Perspect Med. 2014; 4a014373
- PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway[J].J Cell Physiol. 2021; 236: 2767-2781
- Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo[J].J. Cancer Res. Clin. Oncol. 2018; 144: 1685-1699
- IGHG1 regulates prostate cancer growth via the MEK/ERK/c-Myc pathway[J].Biomed Res Int. 2019; 2019: 1-10
Article info
Publication history
Published online: August 20, 2022
Accepted:
July 14,
2022
Received:
March 22,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
